Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help community pharmacies with (a) funding, (b) workforce and (c) supply of medicines.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Government is committed to expanding the pharmacy workforce and better utilising the skills of pharmacists and pharmacy technicians. That includes making prescribing part of the services delivered by community pharmacists, as we shift care from the hospital to the community.
We have inherited ongoing global supply problems that continue to impact medicine availability. We know how frustrating this can be for patients and community pharmacists. We are working closely with industry, the National Health Service, manufacturers, and other partners in the supply chain to resolve issues as quickly as possible to make sure patients can access the medicines they need.
Now that the budget for the Government has been set, we will shortly be resuming our consultation with Community Pharmacy England regarding the funding arrangements for 2024/25. We are unable to say more until these have been concluded.
Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the findings of Lord Darzi's Independent investigation of the NHS in England, published on 12 September 2024, what steps his Department is taking to support community pharmacies with (a) funding, (b) workforce and (c) medicine supply challenges.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
We are committed to expanding the role of pharmacies and better utilising the skills of pharmacists and pharmacy technicians. From 2026, all newly qualified pharmacists will be independent prescribers, and we are investing in training legacy staff to develop clinical and technical roles.
The consultation with Community Pharmacy England on the national funding and contractual framework arrangements has not yet been concluded, and we are looking into this as a matter of urgency.
We have inherited ongoing global supply problems that continue to impact medicine availability. We know how frustrating this can be for patients and community pharmacists. We are working closely with industry, the National Health Service, manufacturers, and other partners in the supply chain to resolve issues as quickly as possible to make sure patients can access the medicines they need.
Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many veterans are receiving specialist mental health support.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Veterans can access specialist mental health support either through Op COURAGE, a bespoke integrated mental health pathway for veterans, or NHS Talking Therapies. As of 30 June 2024, Op COURAGE reported that they were actively supporting 2,702 veterans. Since its inception in April 2017, there have been over 38,500 referrals to Op COURAGE. In addition to the Op COURAGE services, between 1 April 2020 and 30 June 2024, 63,810 veterans have entered NHS Talking Therapy treatment services.
Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of the processes for supporting patients presenting to General Practitioners with mental health disorders attributable to gambling.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
We are committed to supporting improvements to the existing treatment system, ensuring people experiencing gambling-related harm are able to access the right care at the right time.
NHS England now operates 15 specialist gambling treatment clinics, up from two in 2019, with representation across every region in England. Through these clinics, the National Health Service has capacity to treat up to 3,000 people experiencing gambling-related harms each year.
General practitioners are responsible for ensuring their own clinical knowledge remains up-to-date and for identifying learning needs as part of their continuing professional development. This activity should include taking account of new research and developments in guidance, such as that produced by the National Institute for Health and Care Excellence (NICE), to ensure that they can continue to provide high quality care to all patients.
The NICE is currently developing a gambling-related harms guideline, focused on identification, assessment, and management of people who may be harmed by gambling. Publication is expected later this year.
Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to fund research into treatment for vitiligo.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department funds research through the National Institute for Health and Care Research (NIHR). The NIHR welcomes funding applications for research into any aspect of human health, including vitiligo. All research proposals compete for available funding. Applications undergo peer review and are judged based on their importance to patients and health services, value for money, and scientific quality. Funding in any disease area depends on the volume and quality of scientific activity. The NIHR has funded research on various aspects of skin diseases, including specifically on vitiligo home interventions, light therapy, ruxolitinib treatment, and the quality of vitiligo randomised controlled trials. The NIHR has also analysed research evidence on the use of ruxolitinib for treating vitiligo as part of an ongoing National Institute for Health and Care Excellence technology appraisal.